Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acambis Inc.
ACAM2000 has similar success rate, antibody response, and safety as Dryvax
July 6th, 2005
ACAM2000 has similar success rate, antibody response, and safety as Dryvax. According to recent research from the United States, "Despite the eradication of smallpox as a naturally occurring disease, concern persists over its potential use as a bioterrorist agent. The development of a new-generation smallpox vaccine represents an important contribution to a cogent biodefense strategy." A.W. Artenstein and colleagues, Acambis Inc., Cambridge explained, "We conducted a phase 2 randomized, double-blind, controlled trial at four sites in the United States to determine whether a clonal smallpox vaccine manufactured in cell culture, ACAM2000, is equivalent...
Source: Biotech Week (2005-07-06)
|
